Please check your internet connection and try again.
```markdown
# Megestrol Acetate (Megace ES, Megace)
## Overview
Megestrol acetate is a synthetic progestin with antiestrogenic and antineoplastic properties. It is available in oral suspension and tablet forms.
## Primary Indications
* **Cachexia, anorexia, or unexplained significant weight loss** associated with Acquired Immunodeficiency Syndrome (AIDS).
* **Palliative treatment of advanced endometrial carcinoma**.
## Adult Dosing
* **AIDS-related cachexia/anorexia:**
* Oral Suspension (40 mg/mL): 625 mg (approximately 15.6 mL) once daily.
* Tablets (200 mg or 400 mg): No standard tablet dose; suspension preferred for this indication.
* *Maximum dose:* Not clearly defined for this indication.
* **Endometrial carcinoma:**
* Oral Suspension (40 mg/mL): 400 mg to 800 mg (approximately 10 mL to 20 mL) once daily.
* Tablets (200 mg or 400 mg): 400 mg to 800 mg once daily.
* *Maximum dose:* 800 mg daily.
## Pediatric Dosing
Megestrol acetate is not recommended for use in pediatric patients.
## Dose Adjustments
* **Renal impairment:** No specific dose adjustments are recommended.
* **Hepatic impairment:** No specific dose adjustments are recommended, but caution is advised due to potential effects on liver function.
## Contraindications
* Known or suspected pregnancy.
* Known hypersensitivity to megestrol acetate or any component of the formulation.
## Adverse Effects
* **Common:** Weight gain (often due to fluid retention), hot flashes, hypertension, nausea, diarrhea, rash, carpal tunnel syndrome, shortness of breath, vaginal bleeding/spotting, amenorrhea.
* **Serious:** Adrenal insufficiency (especially with abrupt discontinuation after prolonged use), thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism), hyperglycemia, new-onset diabetes or exacerbation of existing diabetes, Cushing's syndrome, hair loss, opportunistic infections.
## Key Drug Interactions
* **CYP3A4 inhibitors (e.g., ketoconazole, ritonavir):** May increase megestrol acetate plasma concentrations, potentially increasing the risk of adverse effects. Monitor closely.
* **CYP3A4 inducers (e.g., rifampin, phenytoin):** May decrease megestrol acetate plasma concentrations, potentially reducing efficacy. Monitor closely.
* **Insulin and oral antidiabetic agents:** Megestrol acetate can cause hyperglycemia. Increased doses of antidiabetic agents may be required. Monitor blood glucose closely.
## Monitoring
* **Weight and appetite:** Regularly assess for effectiveness in cachexia.
* **Blood pressure:** Monitor for hypertension.
* **Blood glucose:** Monitor for hyperglycemia, especially in patients with diabetes or at risk.
* **Electrolytes:** Assess as clinically indicated.
* **Signs of adrenal insufficiency:** Monitor for symptoms like fatigue, weakness, nausea, vomiting, and hypotension, particularly with prolonged use or abrupt discontinuation.
* **Thromboembolic events:** Educate patients on signs and symptoms and monitor.
## Clinical Pearls
* The suspension form is generally preferred for the treatment of AIDS-related cachexia due to the higher doses required.
* Do not abruptly discontinue megestrol acetate after prolonged use, especially at higher doses, due to the risk of adrenal insufficiency. Taper the dose if necessary.
* Weight gain may be significant but is often related to fluid retention.
* Educate patients about the potential for hyperglycemia and the importance of monitoring blood glucose.
* Counsel patients on signs and symptoms of thromboembolic events and adrenal insufficiency.
---
*This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines before making treatment decisions. Dosing and recommendations may vary based on individual patient factors and local protocols.*
```
